Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Research & Development (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Research & Development for 14 consecutive years, with $25.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 24.35% year-over-year to $25.4 million, compared with a TTM value of $107.8 million through Dec 2025, down 20.13%, and an annual FY2025 reading of $107.8 million, down 20.13% over the prior year.
  • Research & Development was $25.4 million for Q4 2025 at Fate Therapeutics, down from $25.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $87.2 million in Q4 2022 and bottomed at $25.4 million in Q4 2025.
  • Average Research & Development over 5 years is $47.6 million, with a median of $37.8 million recorded in 2023.
  • The sharpest move saw Research & Development surged 80.07% in 2021, then tumbled 63.51% in 2023.
  • Year by year, Research & Development stood at $69.5 million in 2021, then grew by 25.43% to $87.2 million in 2022, then crashed by 63.51% to $31.8 million in 2023, then grew by 5.64% to $33.6 million in 2024, then fell by 24.35% to $25.4 million in 2025.
  • Business Quant data shows Research & Development for FATE at $25.4 million in Q4 2025, $25.8 million in Q3 2025, and $27.4 million in Q2 2025.